{
    "clinical_study": {
        "@rank": "124346", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Other", 
                "description": "No active ingredient"
            }, 
            {
                "arm_group_label": "PEAK ATP\u00ae with GlycoCarn\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)and Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)"
            }, 
            {
                "arm_group_label": "PEAK ATP\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)"
            }, 
            {
                "arm_group_label": "GlycoCarn\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)"
            }
        ], 
        "brief_summary": {
            "textblock": "To purpose of this study is to assess the effectiveness, safety and tolerability of PEAK\n      ATP\u00ae with GlycoCarn\u00ae, PEAK ATP\u00ae and GlycoCarn\u00ae on levels of blood sugar and endothelial\n      function improvement which may lead to improved vascular health."
        }, 
        "brief_title": "Comparing Blood Sugar Levels and Endothelial Function of PEAK ATP\u00ae With GlycoCarn\u00ae, PEAK ATP\u00ae and GlycoCarn\u00ae Supplements", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Blood Sugar", 
            "Endothelial Function"
        ], 
        "detailed_description": {
            "textblock": "This study is a randomized, double-blind, placebo-controlled, parallel design to evaluate\n      the effectiveness, safety and tolerability of the study substances utilized to support\n      improved healthy levels of blood sugar and endothelial function.  Each subject will be\n      randomized to receive a specific dose of PEAK ATP\u00ae (Adenosine 5'-Triphosphate Disodium\n      Salt)with GlycoCarn\u00ae (Glycine Propionyl-L-Carnitine Hydrochloride, USP (United States\n      Pharmacopeia) , PEAK ATP\u00ae (Adenosine 5'-Triphosphate Disodium Salt) and GlycoCarn\u00ae (Glycine\n      Propionyl-L-Carnitine Hydrochloride, USP )or Placebo twice daily.\n\n      Participants will undergo assessment of blood tests, brachial ultrasound for determining the\n      change in flow mediated dilation, body weight, % body fat, BMI, waist/hip circumference and\n      blood pressure.\n\n      The primary objective of the study is to evaluate the safety, tolerability and effectiveness\n      of PEAK ATP\u00ae with GlycoCarn\u00ae, PEAK ATP\u00ae and GlycoCarn\u00ae  on improving levels of blood sugar\n      via assessment of plasma glucose.\n\n      Secondary objectives:\n\n        1. To assess flow-mediated dilation as determined by brachial ultrasound evaluation.\n\n        2. To assess the effect on changes in blood levels of HbA1C, high-sensitivity C-Reactive\n           Protein (hs-CRP), Insulin, Nitric Oxide (NOx), Malondialdehyde (MAL), Soluble\n           Inter-cellular Adhesion Molecule-1 (sICAM-1) and E-Selectin.\n\n        3. To assess the effect on body weight, Body Mass Index (BMI), % body fat as measured by\n           skin caliper, waist and hip circumference, and blood pressure.\n\n        4. To assess the effect on general and sexual health for males and females as determined\n           through questionnaires."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Primary Inclusion Criteria:\n\n          -  Ambulatory\n\n          -  Having the following two criteria:\n\n               1. Confirmed as being overweight (BMI of 25.0-39.9)\n\n               2. Confirmed by a baseline fasting blood sugar level between 95.0-125.0 mg/dl with\n                  the glucose meter via finger stick OR laboratory evaluation of glucose level\n                  between 95.0-125.0 mg/dl\n\n          -  Having no difficulty with digestion or absorption of food\n\n        Primary Exclusion Criteria:\n\n          -  Having ever received a clinical diagnosis of cardiovascular disease (excluding\n             hypertension), cancer (excluding basal or squamous cell skin cancer), autoimmune\n             disease (such as systemic lupus, rheumatoid arthritis, multiple sclerosis, psoriasis,\n             etc.), gout, seizures, liver or kidney disease, gallbladder disease, thyroid disease,\n             bi-polar disorder, manic depression, schizophrenia, apathetic (inherited) depression,\n             or any other diagnosis that would preclude study participation in the judgment of the\n             investigator/sub-investigator.\n\n          -  Having ever received a diagnosis of diabetes mellitus, glucose intolerance, or\n             currently taking any medications for either of the aforementioned conditions.\n\n          -  Having ever had a re-vascularization procedure (bypass, angioplasty or stent\n             placement) or having received an organ transplant, pacemaker, or internal medical\n             device.\n\n          -  Currently receiving hormone replacement therapy or taking phosphodiesterase type-5\n             (PDE-5) inhibitors such as Sildenafil, Vardenafil and Tadalafil.\n\n          -  If taking aspirin, ibuprofen, naproxen or other anti-inflammatory medication(s),\n             cholesterol medications (including statins), an oral contraceptive, blood pressure\n             medications or medications to treat congestive heart failure (including ACE\n             inhibitors, ACE antagonists or diuretics), must have been on a stable dose for\n             greater than 3 months prior to baseline and be willing to remain on stable dose for\n             duration of study.\n\n          -  If taking any other cardiovascular drugs including but not limited to antiarrhythmics\n             (excluding beta blockers), inotropic agents, antianginals, or digitalis.\n\n          -  Having had a history of any medical or surgical procedure that would preclude\n             participation in the study in the judgment of the investigator/sub- investigator.\n\n          -  Having any blood coagulation disorder or vitamin K deficiency.\n\n          -  History of allergy to any nutritional supplements, herbal remedies, foods, or any of\n             the components in the study products.\n\n          -  Have no clinically significant abnormalities on the basis of medical history,\n             physical examination, laboratory evaluation and vital signs in the judgment of the\n             investigator and/or sub-investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855373", 
            "org_study_id": "CL049"
        }, 
        "intervention": [
            {
                "arm_group_label": "PEAK ATP\u00ae with GlycoCarn\u00ae", 
                "description": "PEAK ATP\u00ae with GlycoCarn\u00ae {Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule) and Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)}: 2 capsules twice daily on an empty stomach", 
                "intervention_name": "PEAK ATP\u00ae with GlycoCarn\u00ae", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "PEAK ATP\u00ae", 
                "description": "PEAK ATP\u00ae (Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule): 2 capsules twice daily on an empty stomach", 
                "intervention_name": "PEAK ATP\u00ae", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "GlycoCarn\u00ae", 
                "description": "GlycoCarn\u00ae (Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule): 2 capsules twice daily on an empty stomach", 
                "intervention_name": "GlycoCarn\u00ae", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo: 2 capsules twice daily on an empty stomach", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Blood Sugar", 
            "Endothelial Function", 
            "Blood Vessel Health"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "contact": {
                "email": "inin@lifeextension.com", 
                "last_name": "Iliana Nin, CCRC", 
                "phone": "954-202-7737"
            }, 
            "contact_backup": {
                "email": "shirsh@lifeextension.com", 
                "last_name": "Dr. Steven Hirsh", 
                "phone": "954-202-7679"
            }, 
            "facility": {
                "address": {
                    "city": "Fort Lauderdale", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33308"
                }, 
                "name": "Life Extension Clinical Research Inc."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled Study Comparing the Healthy Levels of Blood Sugar and Endothelial Function of PEAK ATP\u00ae With GlycoCarn\u00ae, PEAK ATP\u00ae and GlycoCarn\u00ae Supplementation Versus Placebo", 
        "overall_contact": {
            "email": "shirsh@lifeextension.com", 
            "last_name": "Dr. Steven Hirsh", 
            "phone": "954-202-7679"
        }, 
        "overall_official": {
            "affiliation": "Life Extension", 
            "last_name": "Steven Joyal, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean change in plasma glucose", 
            "safety_issue": "No", 
            "time_frame": "90 days"
        }, 
        "reference": [
            {
                "PMID": "19008000", 
                "citation": "Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: an overview. Trends Neurosci. 2009 Jan;32(1):19-29. doi: 10.1016/j.tins.2008.10.001. Epub 2008 Nov 12. Review."
            }, 
            {
                "PMID": "15940776", 
                "citation": "Bannwarth B, Allaert FA, Avouac B, Rossignol M, Rozenberg S, Valat JP. A randomized, double-blind, placebo controlled triphosphate in study of oral adenosine subacute low back pain. J Rheumatol. 2005 Jun;32(6):1114-7."
            }, 
            {
                "PMID": "18053183", 
                "citation": "Bloomer RJ, Smith WA, Fisher-Wellman KH. Glycine propionyl-L-carnitine increases plasma nitrate/nitrite in resistance trained men. J Int Soc Sports Nutr. 2007 Dec 3;4:22."
            }, 
            {
                "PMID": "10553793", 
                "citation": "Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA. 1999 Nov 3;282(17):1659-64."
            }, 
            {
                "PMID": "12908852", 
                "citation": "Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet. 2003;42(11):941-67. Review."
            }, 
            {
                "PMID": "19341458", 
                "citation": "Jacobs PL, Goldstein ER, Blackburn W, Orem I, Hughes JJ. Glycine propionyl-L-carnitine produces enhanced anaerobic work capacity with reduced lactate accumulation in resistance trained males. J Int Soc Sports Nutr. 2009 Apr 2;6:9. doi: 10.1186/1550-2783-6-9."
            }, 
            {
                "PMID": "15179168", 
                "citation": "Jordan AN, Jurca R, Abraham EH, Salikhova A, Mann JK, Morss GM, Church TS, Lucia A, Earnest CP. Effects of oral ATP supplementation on anaerobic power and muscular strength. Med Sci Sports Exerc. 2004 Jun;36(6):983-90."
            }, 
            {
                "PMID": "6250450", 
                "citation": "Knowles JR. Enzyme-catalyzed phosphoryl transfer reactions. Annu Rev Biochem. 1980;49:877-919. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855373"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean change in flow-mediated dilation", 
                "safety_issue": "No", 
                "time_frame": "90 day"
            }, 
            {
                "measure": "Mean change in HbA1C", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Mean change in high-sensitivity C-Reactive Protein (hs-CRP)", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Mean change in insulin level", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Mean change in Malondialdehyde level", 
                "safety_issue": "No", 
                "time_frame": "90 day"
            }, 
            {
                "measure": "Mean change in soluble Intercellular Adhesion Molecule-1 (sICAM-1)", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Mean change in E-Selectin blood level", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Mean change in body weight", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Mean change in Body Mass Index (BMI)", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Mean change in percent body fat", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Mean change in waist and hip circumference", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Mean change in blood pressure", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Assess the safety and tolerability as measured by various laboratory markers, vital signs and adverse events", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }
        ], 
        "source": "Supplement Formulators, Inc.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Sigma Tau HealthScience LLC", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "TSI Health Sciences Inc.", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Supplement Formulators, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}